Literature DB >> 18190862

Development and application of Hsp90 inhibitors.

David B Solit1, Gabriela Chiosis.   

Abstract

Heat shock protein 90 has emerged as an important target in several diseases. The present review will discuss our understanding of the role played by Hsp90 in regulating and maintaining the transformed phenotype in cancers and neurodegenerative diseases, as well as recent findings on its roles in fungal and viral infections. It will also update the reader on the preclinical development and clinical translation of Hsp90 inhibitors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18190862     DOI: 10.1016/j.drudis.2007.10.007

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  87 in total

1.  A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs.

Authors:  Ho-Chul Shin; Adam W G Alani; Hyunah Cho; Younsoo Bae; Jill M Kolesar; Glen S Kwon
Journal:  Mol Pharm       Date:  2011-06-23       Impact factor: 4.939

2.  Protein analysis of purified respiratory syncytial virus particles reveals an important role for heat shock protein 90 in virus particle assembly.

Authors:  Anuradha Radhakrishnan; Dawn Yeo; Gaie Brown; Myint Zu Myaing; Laxmi Ravi Iyer; Roland Fleck; Boon-Huan Tan; Jim Aitken; Duangmanee Sanmun; Kai Tang; Andy Yarwood; Jacob Brink; Richard J Sugrue
Journal:  Mol Cell Proteomics       Date:  2010-06-08       Impact factor: 5.911

3.  In silico analyses of proteomic data suggest a role for heat shock proteins in umbilical cord blood hematopoietic stem cells.

Authors:  Angelo D'Alessandro; Giuliano Grazzini; Bruno Giardina; Lello Zolla
Journal:  Stem Cell Rev Rep       Date:  2010-12       Impact factor: 5.739

4.  Split Renilla luciferase protein fragment-assisted complementation (SRL-PFAC) to characterize Hsp90-Cdc37 complex and identify critical residues in protein/protein interactions.

Authors:  Yiqun Jiang; Denzil Bernard; Yanke Yu; Yehua Xie; Tao Zhang; Yanyan Li; Joseph P Burnett; Xueqi Fu; Shaomeng Wang; Duxin Sun
Journal:  J Biol Chem       Date:  2010-04-22       Impact factor: 5.157

5.  KRIBB11 inhibits HSP70 synthesis through inhibition of heat shock factor 1 function by impairing the recruitment of positive transcription elongation factor b to the hsp70 promoter.

Authors:  Young Ju Yoon; Joo Ae Kim; Ki Deok Shin; Dae-Seop Shin; Young Min Han; Yu Jin Lee; Jin Soo Lee; Byoung-Mog Kwon; Dong Cho Han
Journal:  J Biol Chem       Date:  2010-11-15       Impact factor: 5.157

6.  Interactions between Hsp90 and oncogenic viruses: implications for viral cancer therapeutics.

Authors:  Michael R Defee; Zhiqiang Qin; Lu Dai; Jennifer S Isaacs; Chris H Parsons
Journal:  Am J Cancer Res       Date:  2011-06-05       Impact factor: 6.166

Review 7.  Proteomic identification of multitasking proteins in unexpected locations complicates drug targeting.

Authors:  Georgina S Butler; Christopher M Overall
Journal:  Nat Rev Drug Discov       Date:  2009-12       Impact factor: 84.694

Review 8.  New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.

Authors:  Yanyan Li; Tao Zhang; Steven J Schwartz; Duxin Sun
Journal:  Drug Resist Updat       Date:  2009 Feb-Apr       Impact factor: 18.500

9.  HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way.

Authors:  Bin Peng; Limin Xu; Fanfan Cao; Tingxuan Wei; Chunxin Yang; Georges Uzan; Denghai Zhang
Journal:  Mol Cancer       Date:  2010-04-16       Impact factor: 27.401

10.  Measurement of nanomolar dissociation constants by titration calorimetry and thermal shift assay - radicicol binding to Hsp90 and ethoxzolamide binding to CAII.

Authors:  Asta Zubrienė; Jurgita Matulienė; Lina Baranauskienė; Jelena Jachno; Jolanta Torresan; Vilma Michailovienė; Piotras Cimmperman; Daumantas Matulis
Journal:  Int J Mol Sci       Date:  2009-06-10       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.